Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with Type 1 diabetes (T1D) or Type 2 diabetes (T2D)~* Body mass Index (BMI) of 18.5 to 30.0 kilograms per meter squared (kg/m2) for T1D, or 18.5 to 35.0 kg/m2 for T2D~* Hemoglobin A1c (HbA1c) ≤10%~Exclusion Criteria:~* Have significant changes in insulin regimen and/ or unstable blood sugar control within the past 3 month~* Have received a total daily dose of insulin \>1.2 units per kilogram (U/kg)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Glucagon Nasal Powder (Type: EXPERIMENTAL): A single dose of 3 milligram (mg) glucagon nasal powder administered intranasally.
- Glucagon Hydrochloride Solution (Type: ACTIVE_COMPARATOR): A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM)

Based on this trial design, predict the completion outcome and termination type (if applicable).